Sveriges mest populära poddar
BioCentury This Week
VetenskapLife Science

Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

25 min•9 maj 2023

Acelyrin last week parlayed a late-stage asset for hidradenitis suppurativa and veteran leadership into one of biotech’s largest-ever NASDAQ IPOs. On the latest BioCentury This Week podcast, BioCentury’s editors discussed how Acelyrin generated outsized demand for its offering and assessed Alzheimer’s data for Eli Lilly's donanemab, the promise and challenges of digital endpoints and takeaways from the latest BioCentury Show, which featured incoming FogPharma CEO Mathai Mammen in conversation with Editor in Chief Simone Fishburn. This week’s podcast is sponsored by Cancer Research Horizons.

Reach us by sending a text

Fler avsnitt av BioCentury This Week

Visa alla avsnitt av BioCentury This Week
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
•29 min
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
•34 min
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
•25 min
Ep. 354 - East-West Summit Takeaways
•26 min
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
•37 min
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
•35 min
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
•35 min
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
•26 min
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
•34 min
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
•31 min

BioCentury This Week med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.